A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top